DE19939981A1 - Neue Inhibitoren des Integrins alphavß3 - Google Patents

Neue Inhibitoren des Integrins alphavß3

Info

Publication number
DE19939981A1
DE19939981A1 DE19939981A DE19939981A DE19939981A1 DE 19939981 A1 DE19939981 A1 DE 19939981A1 DE 19939981 A DE19939981 A DE 19939981A DE 19939981 A DE19939981 A DE 19939981A DE 19939981 A1 DE19939981 A1 DE 19939981A1
Authority
DE
Germany
Prior art keywords
ylamino
acid
phenyl
compounds
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE19939981A
Other languages
German (de)
English (en)
Inventor
Alfred Jonczyk
Oliver Schadt
Simon Goodman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Priority to DE19939981A priority Critical patent/DE19939981A1/de
Priority to JP2001518427A priority patent/JP2003507458A/ja
Priority to PCT/EP2000/007591 priority patent/WO2001014338A1/de
Priority to CN00811950A priority patent/CN1370147A/zh
Priority to BR0013504-6A priority patent/BR0013504A/pt
Priority to CA002382850A priority patent/CA2382850A1/en
Priority to AU65705/00A priority patent/AU6570500A/en
Priority to SK228-2002A priority patent/SK2282002A3/sk
Priority to EP00953158A priority patent/EP1206454A1/de
Priority to KR1020027001419A priority patent/KR20020016651A/ko
Priority to PL00352989A priority patent/PL352989A1/xx
Priority to MXPA02001861A priority patent/MXPA02001861A/es
Priority to HU0203697A priority patent/HUP0203697A3/hu
Priority to CZ2002523A priority patent/CZ2002523A3/cs
Publication of DE19939981A1 publication Critical patent/DE19939981A1/de
Priority to NO20020886A priority patent/NO20020886L/no
Priority to ZA200202287A priority patent/ZA200202287B/en
Priority to HK03101785.4A priority patent/HK1049666A1/zh
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44—Nitrogen atoms not forming part of a nitro radical
    • C07D233/48—Nitrogen atoms not forming part of a nitro radical with acyclic hydrocarbon or substituted acyclic hydrocarbon radicals, attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE19939981A 1999-08-24 1999-08-24 Neue Inhibitoren des Integrins alphavß3 Withdrawn DE19939981A1 (de)

Priority Applications (17)

Application Number Priority Date Filing Date Title
DE19939981A DE19939981A1 (de) 1999-08-24 1999-08-24 Neue Inhibitoren des Integrins alphavß3
KR1020027001419A KR20020016651A (ko) 1999-08-24 2000-08-04 신규한 인테그린 αｖβ３억제제
PL00352989A PL352989A1 (en) 1999-08-24 2000-08-04 Novel integrin alphav
CN00811950A CN1370147A (zh) 1999-08-24 2000-08-04 新型整合蛋白αvβ3抑制剂
BR0013504-6A BR0013504A (pt) 1999-08-24 2000-08-04 Inibidores da integrina alfav beta3
CA002382850A CA2382850A1 (en) 1999-08-24 2000-08-04 Novel inhibitors of the integrin .alpha.v.beta.3
AU65705/00A AU6570500A (en) 1999-08-24 2000-08-04 Novel integrin alphavbeta3 inhibitors
SK228-2002A SK2282002A3 (en) 1999-08-24 2000-08-04 Integrin alpha'v'beta'3' inhibitors, process for the preparation and use thereof and pharmaceutical composition comprising same
EP00953158A EP1206454A1 (de) 1999-08-24 2000-08-04 NEUE INHIBITOREN DES INTEGRINS ALPHAvBETA3
JP2001518427A JP2003507458A (ja) 1999-08-24 2000-08-04 新規なインテグリンαｖβ３阻害剤
PCT/EP2000/007591 WO2001014338A1 (de) 1999-08-24 2000-08-04 NEUE INHIBITOREN DES INTEGRINS αVβ¿3?
MXPA02001861A MXPA02001861A (es) 1999-08-24 2000-08-04 Nuevos inhbidores de la integrina alfav beta3.
HU0203697A HUP0203697A3 (en) 1999-08-24 2000-08-04 Novel integrin alphavbetha3 inhibitors, pharmaceutical compositions containing them and their use
CZ2002523A CZ2002523A3 (cs) 1999-08-24 2000-08-04 Inhibitory integrinu alfa v beta 3
NO20020886A NO20020886L (no) 1999-08-24 2002-02-22 Nye integrin- <alfa>v<beta>3-inhibitorer
ZA200202287A ZA200202287B (en) 1999-08-24 2002-03-20 Novel integrin alphavbeta3 inhibitors.
HK03101785.4A HK1049666A1 (zh) 1999-08-24 2003-03-12 新型整合蛋白αVβ3抑制劑

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19939981A DE19939981A1 (de) 1999-08-24 1999-08-24 Neue Inhibitoren des Integrins alphavß3

Publications (1)

Publication Number Publication Date
DE19939981A1 true DE19939981A1 (de) 2001-03-01

Family

ID=7919343

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19939981A Withdrawn DE19939981A1 (de) 1999-08-24 1999-08-24 Neue Inhibitoren des Integrins alphavß3

Country Status (17)

Country Link
EP (1) EP1206454A1 (es)
JP (1) JP2003507458A (es)
KR (1) KR20020016651A (es)
CN (1) CN1370147A (es)
AU (1) AU6570500A (es)
BR (1) BR0013504A (es)
CA (1) CA2382850A1 (es)
CZ (1) CZ2002523A3 (es)
DE (1) DE19939981A1 (es)
HK (1) HK1049666A1 (es)
HU (1) HUP0203697A3 (es)
MX (1) MXPA02001861A (es)
NO (1) NO20020886L (es)
PL (1) PL352989A1 (es)
SK (1) SK2282002A3 (es)
WO (1) WO2001014338A1 (es)
ZA (1) ZA200202287B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1289960A2 (en) 2000-06-15 2003-03-12 Pharmacia Corporation Cycloalkyl alkanoic acids as integrin receptor antagonists
US6531494B1 (en) 2001-08-29 2003-03-11 Pharmacia Corporation Gem-substituted αvβ3 antagonists
MXPA06006319A (es) * 2003-12-03 2006-08-23 Scripps Research Inst Peptidos y anticuerpos especificos para integrina aiib??3.
WO2006043930A1 (en) * 2004-10-14 2006-04-27 Pharmacia Corporation Biphenyl integrin antagonists
PT3538528T (pt) * 2016-11-08 2021-02-16 Bristol Myers Squibb Co Pirrol amidas como inibidores de integrina v

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08325264A (ja) * 1995-05-31 1996-12-10 Sumitomo Metal Ind Ltd 新規２−芳香環置換−３−フェニルプロピオン酸またはアクリル酸誘導体
JP2001504456A (ja) * 1996-10-30 2001-04-03 メルク エンド カンパニー インコーポレーテッド インテグリン拮抗薬
TR200002625T2 (tr) * 1998-03-10 2000-12-21 Smithkline Beecham Corporation Vitronektin Reseptörü Antagonistleri

Also Published As

Publication number Publication date
HK1049666A1 (zh) 2003-05-23
BR0013504A (pt) 2002-05-07
AU6570500A (en) 2001-03-19
NO20020886D0 (no) 2002-02-22
CZ2002523A3 (cs) 2002-05-15
KR20020016651A (ko) 2002-03-04
SK2282002A3 (en) 2002-06-04
MXPA02001861A (es) 2004-09-06
JP2003507458A (ja) 2003-02-25
HUP0203697A3 (en) 2004-04-28
CA2382850A1 (en) 2001-03-01
CN1370147A (zh) 2002-09-18
PL352989A1 (en) 2003-09-22
EP1206454A1 (de) 2002-05-22
WO2001014338A1 (de) 2001-03-01
HUP0203697A2 (hu) 2003-03-28
NO20020886L (no) 2002-02-22
ZA200202287B (en) 2003-08-27

Similar Documents

Publication Publication Date Title
DE19548709A1 (de) Tyrosinderivate
EP0907637A1 (de) Phenylalanin-derivate als integrin-inhibitoren
DE19654483A1 (de) Phenylalanin-Derivate
EP1097127B1 (de) Diacylhydrazinderivate als integrin-inhibitoren
EP0964856B1 (de) Bicyclische aromatische aminosäuren
DE10112771A1 (de) Inhibitoren des Integrins alpha¶v¶beta¶6¶
DE10006139A1 (de) Indol-3-yl-Derivate
DE19850131A1 (de) Chromenon- und Chromanonderivate
EP1153014B1 (de) Beta-alaninderivate
DE10204789A1 (de) Inhibitoren des Integrins alpha¶v¶beta6
DE19939980A1 (de) Inhibitoren des Integrins alphavbeta¶3¶
DE19713000A1 (de) Adhäsionsrezeptor-Antagonisten
EP1194401B1 (de) Diacylhydrazinderivate
DE10118550A1 (de) Liganden des Integrins alpha¶nu¶beta¶6¶
DE19939981A1 (de) Neue Inhibitoren des Integrins alphavß3
DE19916837A1 (de) Dibenzoazulenderivate
DE10127041A1 (de) Integrinantagonisten
DE19937394A1 (de) Fluorenderivate
DE10139059A1 (de) Thioamide
WO1998018764A1 (de) Dihydrobenzoanthracenone, -pyrimidinone oder dihydronaphthochinolinone

Legal Events

Date Code Title Description
8139 Disposal/non-payment of the annual fee